home / stock / cdtx / cdtx news

CDTX News and Press, Cidara Therapeutics Inc. From 12/05/23

Stock Information
Company Name: Cidara Therapeutics Inc.
Stock Symbol: CDTX
Market: NASDAQ
Website: cidara.com
Menu
CDTX CDTX Quote CDTX Short CDTX News CDTX Articles CDTX Message Board
Get CDTX Alerts

News, Short Squeeze, Breakout and More Instantly...
CDTX - Cidara, Melinta announce publication of Rezzayo data in medical journal

2023-12-05 11:17:43 ET More on Cidara Therapeutics Cidara Therapeutics: Reduced Risk Due To Janssen's Decision And Progress In The Oncology Pipeline Seeking Alpha’s Quant Rating on Cidara Therapeutics Historical earnings data for Cidara Therapeutics Fi...
CDTX - Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing seriou...

CDTX - Cidara Therapeutics Named as a San Diego Metro Area Top Workplace

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing seriou...

CDTX - Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC's 38?? Annual Meeting

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing seriou...
CDTX - Cidara Therapeutics GAAP EPS of -$0.09 beats by $0.06, revenue of $12.72M beats by $4.58M

2023-11-02 17:40:32 ET More on Cidara Therapeutics Cidara Therapeutics: Reduced Risk Due To Janssen's Decision And Progress In The Oncology Pipeline Buy Cidara Therapeutics For The Cloudbreak Platform Cidara Therapeutics: Leveraging Antifungals To Move Into Cancer Th...

CDTX - Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quar...

CDTX - Expected US Company Earnings on Thursday, November 2nd, 2023

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
CDTX - Expected earnings - Cidara Therapeutics Inc.

Cidara Therapeutics Inc. (CDTX) is expected to report $-0.14 for Q3 2023

CDTX - Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program. 2 , 3 If approved by the European Medicines Agency, rezafungin could be the first new tre...

CDTX - Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious dise...
Previous 10 Next 10